Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
about
Risk impact of edoxaban in the management of stroke and venous thromboembolismComparative risk impact of edoxaban in the management of stroke and venous thromboembolismDirect-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine PhysiciansHow we treat bleeding associated with direct oral anticoagulantsAsian Patients with Stroke plus Atrial Fibrillation and the Dose of Non-Vitamin K Oral AnticoagulantsNon-Vitamin K Oral Anticoagulants in Stroke Patients: Practical IssuesReversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumabEdoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous ThromboembolismEmerging Tools for Stroke Prevention in Atrial FibrillationTherapeutic and clinical aspects of portal vein thrombosis in patients with cirrhosisManaging atrial fibrillation in the very elderly patient: challenges and solutionsStroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulantsRisk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-AnalysisNovel antidotes for target specific oral anticoagulantsAtrial fibrillation in heart failure: what should we do?Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and SimilaritiesCognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?Evidence for the prevention and treatment of stroke in dialysis patientsAn evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillationSystematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation.Ablation of Atrial Fibrillation in Combination with Left Atrial Appendage Occlusion in A Single Procedure. Rationale and TechniqueMinimizing bleeding risk in patients receiving direct oral anticoagulants for stroke preventionDOACs - advances and limitations in real worldNonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversalAntithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulationChoosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to KnowReducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?Clinical and Economic Implications of AF Related StrokeRisk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational StudiesEfficacy and safety of novel anticoagulants in the elderlyDirect oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced ageCardiac Plug I and Amulet Devices: Left Atrial Appendage Closure for Stroke Prophylaxis in Atrial FibrillationNon-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused ReviewAtrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillationEfficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-AnalysisAnticoagulation in atrial fibrillationStroke Prevention in Atrial Fibrillation: Focus on Latin AmericaTwice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteriaStroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort studyThromboembolic risk and effect of oral anticoagulation according to atrial fibrillation patterns: A systematic review and meta-analysis
P2860
Q26738846-47FC3A1E-568D-47EE-9946-E57D8257FBCEQ26746233-B1D52E02-F5E2-46F9-8306-53BF75292F86Q26746917-312C8F05-8524-4391-8C93-322D4361A8FBQ26748343-107D325A-69F8-4994-B7DC-A9F7EE46F891Q26750467-7681FF8C-F4E0-4FF4-A927-B92BF7A4F041Q26750767-D65F549B-52E0-40D5-9985-B99728F88731Q26764882-690687E3-668D-4047-BBFF-B403E06CD914Q26764998-04AD5A1B-0229-43AC-AACC-85F15543F3D5Q26765023-E1DF344B-2171-4C20-9DC9-896A842805A3Q26774531-AC1270A3-5698-42F5-B1C5-68EE90C8BE16Q26775877-2FDF0F60-50EF-4413-A260-115FA5DC3BAAQ26781181-6E691396-A24C-4029-8DF2-015E9BD5BA1BQ26783473-01849173-3559-4257-B9E9-87037FE1E8EFQ26784125-3FCFB712-8BFE-4640-8543-9A2DF991211BQ26784426-4D205C94-B620-45CC-B2F1-D955A669A29EQ26787046-B27D5D75-8BDA-4B3F-A811-F02B227BB4FDQ26799394-528A0126-BDA6-4D79-B150-C26F475C61DEQ27023274-9F7F872B-CC7E-4367-A7ED-AAD38BCD25D6Q27027953-3F3D6DBE-5793-40FD-9A2F-B0162A00445EQ27337981-DC447711-CE0B-49C1-8557-9E845AD77BC6Q28068321-C15CAE37-A55E-4517-8FF0-F33AE1CF4DCFQ28069809-FF077A25-F347-42A1-8511-3A100369BB3DQ28070132-002C34EA-1B7B-40CE-85EB-B6E30C421D78Q28071657-1DCD7E58-4392-468B-98F0-C87579B75818Q28072522-C3B64FBF-2A23-4D91-A396-3E2DEA88754EQ28074445-818ED5D9-A44A-42AA-8FC1-1D64698ACBFCQ28077755-FE428162-8EEC-468E-9356-346ED7EFFE79Q28077788-3E093436-183A-4EDB-A822-B06AA07B0591Q28078747-3B99612F-D052-4B6B-8928-A838336F3318Q28079383-B51802CB-5054-44D6-BBE6-D71A9CA18A5AQ28079930-955115FD-9FF0-4D04-83AD-A84A53EAA6E5Q28081426-1773D895-E035-4014-90C4-E453C0C7D151Q28081918-FF5BB441-3A66-48ED-A672-BA4D7E66F9D5Q28084658-0F3AFC28-8B84-44F6-B072-A0CDE8045779Q28085676-43ED2BFE-0195-4468-8DEE-0C753EB12E9EQ28315636-4A444171-B770-4FCD-8D0C-B4FF00AABEA4Q28359631-715A4CAF-890E-4E46-8A57-C74098E88A58Q28539517-16DE49E8-D694-4CC5-8967-C426723ACCE3Q29394400-1A93CC07-01DF-43C2-822F-AB61B20BCA94Q29994528-FD94FFA5-70DF-4C52-92FB-066D7474A7E7
P2860
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Comparison of the efficacy and ...... analysis of randomised trials.
@en
Comparison of the efficacy and ...... analysis of randomised trials.
@nl
type
label
Comparison of the efficacy and ...... analysis of randomised trials.
@en
Comparison of the efficacy and ...... analysis of randomised trials.
@nl
prefLabel
Comparison of the efficacy and ...... analysis of randomised trials.
@en
Comparison of the efficacy and ...... analysis of randomised trials.
@nl
P2093
P50
P921
P1433
P1476
Comparison of the efficacy and ...... analysis of randomised trials.
@en
P2093
A John Camm
Alexander Parkhomenko
Basil S Lewis
Christian T Ruff
Elaine B Hoffman
Jeffrey I Weitz
Michael D Ezekowitz
Naveen Deenadayalu
Takeshi Yamashita
P304
P356
10.1016/S0140-6736(13)62343-0
P407
P577
2013-12-04T00:00:00Z